Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

ABSTRACT:

Background and objectives

Quality of life (QOL) is markedly impaired in patients with anemia, diabetes mellitus, and chronic kidney disease. Limited data exist regarding the effect of anemia treatment on patient perceptions. The objectives were to determine the longitudinal impact of anemia treatment on quality of life in patients with diabetes and chronic kidney disease and to determine the predictors of baseline and change in QOL.

Design, setting, participants, & measurements

In a large, double blind study, patients with type 2 diabetes mellitus, nondialysis chronic kidney disease (estimated GFR, 20 to 60 ml/min per 1.73 m(2)), and anemia (hemoglobin 10.4 g/dl) were randomized to darbepoetin alfa or placebo. QOL was measured with Functional Assessment of Cancer Therapy-Fat

SUBMITTER: Lewis EF 

PROVIDER: S-EPMC3069378 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature